MA71661A - Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées - Google Patents

Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Info

Publication number
MA71661A
MA71661A MA71661A MA71661A MA71661A MA 71661 A MA71661 A MA 71661A MA 71661 A MA71661 A MA 71661A MA 71661 A MA71661 A MA 71661A MA 71661 A MA71661 A MA 71661A
Authority
MA
Morocco
Prior art keywords
enzymes
fusion proteins
related methods
sulfoglucosamine sulfohydrolase
sulfohydrolase
Prior art date
Application number
MA71661A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Mihalis Kariolis
Cathal Mahon
Tina GIESE
Original Assignee
Denali Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc. filed Critical Denali Therapeutics Inc.
Publication of MA71661A publication Critical patent/MA71661A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA71661A 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées MA71661A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091800P 2020-10-14 2020-10-14
PCT/US2021/054860 WO2022081765A1 (fr) 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
EP21811560.8A EP4229192A1 (fr) 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Publications (1)

Publication Number Publication Date
MA71661A true MA71661A (fr) 2025-05-30

Family

ID=78725609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71661A MA71661A (fr) 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Country Status (17)

Country Link
US (2) US11884944B2 (fr)
EP (1) EP4229192A1 (fr)
JP (2) JP2023545707A (fr)
KR (1) KR20230086703A (fr)
CN (1) CN116916947A (fr)
AR (1) AR123788A1 (fr)
AU (2) AU2021362209B2 (fr)
CA (1) CA3197506A1 (fr)
CL (1) CL2023001034A1 (fr)
CO (1) CO2023005260A2 (fr)
CR (1) CR20230178A (fr)
EC (1) ECSP23035251A (fr)
IL (1) IL302029A (fr)
MA (1) MA71661A (fr)
MX (1) MX2023004335A (fr)
PE (1) PE20231931A1 (fr)
WO (1) WO2022081765A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
TW202542190A (zh) * 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2003057179A2 (fr) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Utilisation de p97 en tant que systeme d'administration d'enzymes en vue d'administrer des enzymes lysosomales therapeutiques
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
PL3219795T3 (pl) 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
EP2394667A1 (fr) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
BR112012033214B1 (pt) 2010-06-25 2020-11-03 Shire Human Genetic Therapies, Inc. uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2842492A1 (fr) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. Fragments de p97 avec activite de transfert
WO2014022515A1 (fr) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Protéines de maladie de stockage lysosomal déphosphorylées et leurs procédés d'utilisation
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
WO2014152940A1 (fr) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Compositions thérapeutiques à base d'arnm et leur utilisation pour traiter des maladies et des troubles
US20150023956A1 (en) 2013-07-22 2015-01-22 Armagen Technologies, Inc. Methods and compositions for increasing enzyme activity in the cns
SMT201800511T1 (it) 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
EP3221361B1 (fr) 2014-11-19 2021-04-21 Genentech, Inc. Anticorps multispécifiques anti-récepteur de transferrine / anti-bace1 et procédés d'utilisation
CA2990785C (fr) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. Anticorps anti-recepteur de transferrine humaine passant au travers de la barriere hematoencephalique
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
MY207684A (en) 2015-12-08 2025-03-12 Regeneron Pharma Compositions and methods for internalizing enzymes
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3419651B1 (fr) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Formulation de la protéine de fusion naglu améliorée
CA3033082A1 (fr) 2016-08-06 2018-02-15 Ossianix, Inc. Methodes in vivo pour selectionner des peptides qui traversent la barriere hemato-encephalique, compositions apparentees et procedes d'utilisation
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
EP3556399A1 (fr) 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Conjugué de protéine à action prolongée ciblant le cerveau
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
MX2019007824A (es) 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053379A1 (fr) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anticorps anti-tau et leurs procedes d'utilisation
EP4628586A3 (fr) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Modeles transgeniques du recepteur de la transferrine
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20200157172A1 (en) 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
WO2019032955A1 (fr) 2017-08-10 2019-02-14 Denali Therapeutics Inc. Polypeptides de liaison au récepteur de transferrine modifiés
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
EP3708661A4 (fr) 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. Protéine de fusion d'enzyme thérapeutique à nouvelle structure et son utilisation
BR112020013921A2 (pt) * 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
WO2019145500A1 (fr) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Méthode de traitement
CR20200566A (es) * 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
WO2019246071A1 (fr) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Protéines de fusion comprenant de la progranuline
CA3109763A1 (fr) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Proteines bispecifiques modifiees
EP3840781A1 (fr) 2018-08-22 2021-06-30 Denali Therapeutics Inc. Polypeptides anti-her2 et leurs méthodes d'utilisation
AR119259A1 (es) * 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021146256A1 (fr) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
WO2021158986A1 (fr) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Procédés de traitement de la maladie de hunter
CA3170338A1 (fr) 2020-02-19 2021-08-26 Denali Therapeutics Inc. Proteines bispecifiques anti-her2 modifiees

Also Published As

Publication number Publication date
CL2023001034A1 (es) 2023-10-06
AU2026203601A1 (en) 2026-05-28
KR20230086703A (ko) 2023-06-15
JP2023545707A (ja) 2023-10-31
EP4229192A1 (fr) 2023-08-23
US20240150736A1 (en) 2024-05-09
CN116916947A (zh) 2023-10-20
US11884944B2 (en) 2024-01-30
CA3197506A1 (fr) 2022-04-21
ECSP23035251A (es) 2023-10-31
TW202229547A (zh) 2022-08-01
AU2021362209B2 (en) 2026-02-12
AR123788A1 (es) 2023-01-11
US20230062800A1 (en) 2023-03-02
CO2023005260A2 (es) 2023-05-19
AU2021362209A1 (en) 2023-05-18
MX2023004335A (es) 2023-05-04
WO2022081765A1 (fr) 2022-04-21
CR20230178A (es) 2023-07-26
PE20231931A1 (es) 2023-12-01
JP2026095522A (ja) 2026-06-11
IL302029A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EP2023941A4 (fr) Agents de réticulation de protéine, méthodes de réticulation et leurs applications
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
BRPI0918027A2 (pt) enzimas de lise de peptidoglicano artificial e proteínas de ligação de peptidoglicano
EP4211234A4 (fr) Enzymes d'édition de base
EP4157888A4 (fr) Protéines modifiées et agents de dégradation de protéines
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
MX377150B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
DK3830120T5 (da) Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1
DK1844074T3 (da) Humane antistoffer og proteiner
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP4203998A4 (fr) Protéines de fusion de coronavirus immunogènes et méthodes associées
DK1913136T3 (da) Fusionsproteiner mellem plantecellevæg-nedbrydende enzymer og anvendelser deraf
EP3331543A4 (fr) Conjugués de pénétration cellulaire formés de protéine et d'anticorps et méthodes d'utilisation
FR2908978B1 (fr) Porte-protheses et leurs applications.
ZA201805648B (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
EP4065702A4 (fr) Système et méthodes d'activation d'expression génique
EP4190803A4 (fr) PROTÉINE DE FUSION SIRPa-FC
EP4171603A4 (fr) Protéines de fusion ace2-fc et méthodes d'utilisation
WO2008054595A3 (fr) Étiquettes moléculaires contrôlées par médicament
EP4370594A4 (fr) Enzymes et leurs utilisations
EP4323412A4 (fr) Protéines de fusion et leurs utilisations
EP3943601A4 (fr) Traduction de protéines à l'aide d'arn circulaire et son application
IL313553A (en) Fusion proteins containing alpha-L-iduronidase enzymes and methods
HUE043668T2 (hu) Szemészeti készítmények és alkalmazásuk
EP4289943A4 (fr) Enzyme de désamidation de protéine